CONMED Corporation to Participate in Two Investor Conferences
November 15 2013 - 7:00AM
Marketwired
CONMED Corporation to Participate in Two Investor Conferences
UTICA, NY--(Marketwired - Nov 15, 2013) - CONMED
Corporation (NASDAQ: CNMD), a medical technology company
specializing in medical devices for orthopedic and general surgery,
announced today that the Company will participate in two investor
conferences in New York City as follows:
- Barclays Select Series 2013: Select Growth Conference on
November 18, 2013 at 1:10 PM Eastern
- Piper Jaffray 25th Annual Healthcare Conference on
December 4, 2013 at 11:30 AM Eastern
Mr. Joseph J. Corasanti, President and CEO of CONMED, will
discuss the Company's business. The live webcasts of CONMED's
presentations will be available at www.conmed.com in the Investors
section of the website and will be available for replay through
December 13, 2013.
CONMED profile
CONMED is a medical technology company with an emphasis on
surgical devices and equipment for minimally invasive procedures.
The Company's products are used by surgeons and physicians in a
variety of specialties including orthopedics, general surgery,
gynecology, neurosurgery and gastroenterology. Headquartered in
Utica, New York, the Company's 3,600 employees distribute its
products worldwide from several manufacturing locations. CONMED has
a direct selling presence in 16 countries outside the United States
and international sales constitute approximately 50% of the
Company's total sales.
Forward Looking Information
Certain statements made in the presentation may constitute
forward-looking statements. The forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and relate to the Company's
performance on a going-forward basis. They will be based upon
management's expectations and involve risks and uncertainties which
could cause actual results, performance or trends, to differ
materially from those expressed in the forward-looking statements
therein or in previous disclosures. The Company believes that all
forward-looking statements made by it have a reasonable basis, but
there can be no assurance that management's expectations, beliefs
or projections as expressed in the forward-looking statements will
actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual
results to differ materially from those discussed in the
forward-looking statements include, but are not limited to: (i) the
failure of any one or more of management's assumptions to prove to
be correct; (ii) the risks relating to forward-looking statements
discussed in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K for
the fiscal year ended December 31, 2012 and Quarterly Reports on
Form 10-Q; (iii) cyclical purchasing patterns from customers,
end-users and dealers; (iv) timely release of new products, and
acceptance of such new products by the market; (v) the introduction
of new products by competitors and other competitive responses;
(vi) the possibility that any new acquisition (and its integration)
or other transaction may require the Company to reconsider its
financial assumptions and goals/targets; (vii) increasing costs for
raw material, transportation, or litigation; (viii) the risk of a
lack of allograft tissues due to reduced donations of such tissues
or due to tissues not meeting the appropriate high standards for
screening and/or processing of such tissues; and/or (ix) the
Company's ability to devise and execute strategies to respond to
market conditions.
CONTACT: CONMED Corporation Robert Shallish Chief
Financial Officer 315-624-3206
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Apr 2023 to Apr 2024